Practice question

Answer the question and get instant feedback.

Moderate"The 2022 HF guideline gives SGLT2 inhibitors a Class IIa recommendation to reduce HF hospitalizations in HFpEF. DPP‑4 inhibitors lack HFpEF benefit; nitrates/CCBs are not recommended to improve outcomes; ACEI/ARB may be used for comorbidities but do not reduce HF admissions like SGLT2i."Cardiology"moderate"

A 65-year-old with HFpEF and diabetes on ARB and diuretic has persistent symptoms. Which pharmacotherapy has evidence for reducing HF hospitalization in HFpEF?

Practice more on iatroX

Educational content. Not a substitute for clinical judgement or local policy.